Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026
PR Newswire•30/10/2026•08:00 ET
0
Key Highlights
- ➤Q3 2026 financial results scheduled for November 5 before market open
- ➤Conference call set for 8:00 a.m. ET to review results and provide update
- ➤Phase 3 INVINCIBLE-3 trial tests INT230-6 monotherapy in soft tissue sarcoma
- ➤Phase 2 INVINCIBLE-4 study evaluates INT230-6 in presurgical triple-negative breast cancer
- ➤Two completed INT230-6 studies enrolled over 200 patients
Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026 PR Newswire
Company to hold a conference call at 8AM ET on November 5, 2026 to review results and provide a corporate update
Get started
Create a free account to read the full story.